Welcome to our dedicated page for C21 Investments SEC filings (Ticker: CXXIF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C21 Investments Inc. filings document a foreign issuer that furnishes U.S. current reports on Form 6-K while reporting its cannabis business through interim financial statements, management discussion and analysis, certifications and related news-release exhibits. The filings describe operations in U.S. cannabis cultivation, processing, retail and distribution, including Nevada assets and branded THC and CBD product categories.
These regulatory documents cover consolidated balance sheets, statements of loss and comprehensive loss, shareholders' equity, cash flows and notes prepared in U.S. dollars under U.S. GAAP. They also provide formal disclosure on inventory, property and equipment, right-of-use assets, intangible assets, goodwill, liabilities, capital structure, operating results, issuer-bid activity and management certifications.
C21 Investments Inc. files its annual report on Form 20‑F for the year ended March 31, 2026, outlining its U.S.-focused cannabis operations and extensive risk profile. The company had 117,836,067 common shares outstanding as of March 31, 2026.
The report emphasizes that cannabis remains illegal under U.S. federal law, creating potential exposure to enforcement, banking constraints, money‑laundering rules and Section 280E tax limitations, even as certain medical cannabis products are rescheduled to Schedule III. It also discloses material weaknesses in internal control over financial reporting and highlights operational, regulatory, supply chain, product liability, data privacy and environmental risks.
C21 Investments Inc. files its annual report on Form 20‑F for the year ended March 31, 2026, outlining its U.S.-focused cannabis operations and extensive risk profile. The company had 117,836,067 common shares outstanding as of March 31, 2026.
The report emphasizes that cannabis remains illegal under U.S. federal law, creating potential exposure to enforcement, banking constraints, money‑laundering rules and Section 280E tax limitations, even as certain medical cannabis products are rescheduled to Schedule III. It also discloses material weaknesses in internal control over financial reporting and highlights operational, regulatory, supply chain, product liability, data privacy and environmental risks.
C21 Investments Inc. reported audited results for the year ended March 31, 2026, showing modest growth but continued losses. Revenue from Nevada operations rose to $32.6 million from $30.1 million, with gross profit increasing to $13.6 million.
After selling, general and administrative expenses of $11.3 million and significant income tax expense of $4.6 million, the Company recorded a net loss of $3.2 million, unchanged at a basic and diluted loss per share of $0.03. Cash from operating activities of continuing operations was $1.36 million.
Total assets were $54.4 million and total liabilities $29.0 million, resulting in shareholders’ equity of $25.4 million. Working capital improved to a surplus of $1.9 million, but the balance sheet includes an income tax payable of $1.65 million and an uncertain tax position of $13.36 million linked to U.S. cannabis tax treatment.
C21 Investments Inc. reported audited results for the year ended March 31, 2026, showing modest growth but continued losses. Revenue from Nevada operations rose to $32.6 million from $30.1 million, with gross profit increasing to $13.6 million.
After selling, general and administrative expenses of $11.3 million and significant income tax expense of $4.6 million, the Company recorded a net loss of $3.2 million, unchanged at a basic and diluted loss per share of $0.03. Cash from operating activities of continuing operations was $1.36 million.
Total assets were $54.4 million and total liabilities $29.0 million, resulting in shareholders’ equity of $25.4 million. Working capital improved to a surplus of $1.9 million, but the balance sheet includes an income tax payable of $1.65 million and an uncertain tax position of $13.36 million linked to U.S. cannabis tax treatment.
C21 Investments Inc. reported third-quarter revenue of $8.1 million, up 3% year-over-year, driven by a 4% increase in same-store retail sales despite a 4% decline in overall Nevada cannabis sales. Gross margin fell to 38.2% as pricing pressure and holiday discounting weighed on profitability.
The company generated Income from Operations of $0.4 million and Net Income Before Tax of $0.2 million, but recorded a net loss of $0.6 million, or ($0.01) per share, mainly due to an Income Tax expense of $0.83 million. Adjusted EBITDA was $1.1 million, and Free Cash Flow before working capital changes reached $1.0 million, marking another quarter of positive cash generation.
Current liabilities decreased to $6.3 million at December 31, 2025, from $8.0 million at March 31, 2025, as the company used cash to pay $0.6 million of income tax, retire $0.3 million of debenture principal, and reduce payables and other short-term obligations. C21 maintains an uncertain tax position of $12.0 million related to U.S. Internal Revenue Code Section 280E and has refiled amended U.S. federal income tax returns, which introduces ongoing tax-related risk alongside its continued focus on strategic growth opportunities.
C21 Investments Inc. reported third-quarter revenue of $8.1 million, up 3% year-over-year, driven by a 4% increase in same-store retail sales despite a 4% decline in overall Nevada cannabis sales. Gross margin fell to 38.2% as pricing pressure and holiday discounting weighed on profitability.
The company generated Income from Operations of $0.4 million and Net Income Before Tax of $0.2 million, but recorded a net loss of $0.6 million, or ($0.01) per share, mainly due to an Income Tax expense of $0.83 million. Adjusted EBITDA was $1.1 million, and Free Cash Flow before working capital changes reached $1.0 million, marking another quarter of positive cash generation.
Current liabilities decreased to $6.3 million at December 31, 2025, from $8.0 million at March 31, 2025, as the company used cash to pay $0.6 million of income tax, retire $0.3 million of debenture principal, and reduce payables and other short-term obligations. C21 maintains an uncertain tax position of $12.0 million related to U.S. Internal Revenue Code Section 280E and has refiled amended U.S. federal income tax returns, which introduces ongoing tax-related risk alongside its continued focus on strategic growth opportunities.
C21 Investments Inc. reports Q3 results for the three and nine months ended December 31, 2025, showing modest growth but continued net losses. Quarterly revenue reached $8.14 million, up from $7.91 million a year earlier, driven mainly by Nevada retail sales and the new South Reno dispensary. For the nine-month period, revenue rose to $25.16 million from $22.01 million, while income from operations improved to $1.79 million from $0.44 million.
Despite stronger operations, heavy interest, accretion, and especially income taxes kept the company in the red, with a Q3 net loss of $0.61 million and a nine-month loss of $1.86 million. The effective tax rate reached 299% year-to-date due to U.S. cannabis tax rules, and an uncertain tax position was recorded. C21 generated $0.96 million of operating cash from continuing operations over nine months and ended with cash of $2.42 million and a working capital surplus of $2.01 million.
During the period, C21 closed a $3.5 million South Reno dispensary asset acquisition funded by a C$4 million convertible debenture financing, expanded its Nevada lease portfolio, and continued normal course issuer bid share repurchases. It also settled long-running Eco Firma Farms litigation with a $2.4 million cash obligation and agreement to issue 555,793 shares, offset by extinguishing $1.77 million of related liabilities.
C21 Investments Inc. reports Q3 results for the three and nine months ended December 31, 2025, showing modest growth but continued net losses. Quarterly revenue reached $8.14 million, up from $7.91 million a year earlier, driven mainly by Nevada retail sales and the new South Reno dispensary. For the nine-month period, revenue rose to $25.16 million from $22.01 million, while income from operations improved to $1.79 million from $0.44 million.
Despite stronger operations, heavy interest, accretion, and especially income taxes kept the company in the red, with a Q3 net loss of $0.61 million and a nine-month loss of $1.86 million. The effective tax rate reached 299% year-to-date due to U.S. cannabis tax rules, and an uncertain tax position was recorded. C21 generated $0.96 million of operating cash from continuing operations over nine months and ended with cash of $2.42 million and a working capital surplus of $2.01 million.
During the period, C21 closed a $3.5 million South Reno dispensary asset acquisition funded by a C$4 million convertible debenture financing, expanded its Nevada lease portfolio, and continued normal course issuer bid share repurchases. It also settled long-running Eco Firma Farms litigation with a $2.4 million cash obligation and agreement to issue 555,793 shares, offset by extinguishing $1.77 million of related liabilities.